Status:

TERMINATED

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

Lead Sponsor:

Allergan

Conditions:

Glaucoma

Eligibility:

All Genders

2-17 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess the safety and efficacy of a new formulation of bimatoprost ophthalmic solution compared to timolol ophthalmic solution in the treatment of paediatric patients w...

Eligibility Criteria

Inclusion

  • Diagnosis of congenital, juvenile glaucoma
  • Requires treatment with IOP-lowering medication in one or both eyes

Exclusion

  • Surgical intervention is indicated or planned to lower IOP
  • Abnormally low body weight (below 5th percentile)
  • Any active eye infection or disease
  • Anticipated use of contact lenses during the study
  • Topical ocular steroid use within 2 months
  • History of ocular trauma in either eye
  • Required chronic use of ocular medications (other than study medication) during the study (intermittent use of artificial tears permitted)

Key Trial Info

Start Date :

September 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT01426113

Start Date

September 1 2011

End Date

October 1 2014

Last Update

October 2 2015

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Louisville, Kentucky, United States

2

Amiens, France

3

Milan, Italy

4

Parma, Italy